Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.

Abstract: Provided herein are methods for making, and epitope-targeted, conditionally-activated, pro-drug, antibody, comprising: complementarity determining regions (CDRs) from an antibody identified from an in vivo, in vitro, or in silico antibody library; one or more engineered epitope masks connected to a linker, wherein the linker comprises a peptide, a polymer, or a chemical-linker that is cleaveable in vivo at a target site by an enzyme or cleaved chemically, and wherein the one or more engineered epitope masks binds the epitope-specific antibody at the CDRs of the epitope-specific antibody; and wherein the one or more engineered epitope masks linked to the antibody via the linker, wherein the masks are conditionally bound to the CDRs of the epitope-specific antibody, and wherein cleavage of the linker releases the one or more engineered epitope masks from the antigen binding site.

Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.

Abstract: Provided herein are anti-Trop 2 antibodies or binding fragments thereof that bind Trop 2, e.g., human Trop 2. The anti-Trop 2 antibodies of the disclosure are useful for the treatment of proliferative disorders or cells that express Trop 2 or mutant Trop 2. Also provided herein are methods of use for the anti-Trop 2 antibodies or binding fragments thereof, as well as bi-valent or multi-valent anti-Trop 2 antibodies or binding fragments thereof that may form complexes that attract immune effectors or binding to other cells, such as, a second antibody, antigen-binding of the second antibody or fragment thereof; a target-binding protein, a cytokine; a lectin; or a toxin.

Abstract: Provided herein are novel human anti-CD3 antigen-binding polypeptides, treatments, nucleic acids, vectors, their preparation and their use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.

Abstract: Provided herein are anti-MUC16 antibodies or binding fragments thereof which bind the non-shed domain of MUC16. The anti-MUC16 antibodies or binding fragments thereof of the disclosure are useful for the treatment of cancer cells that shed the extracellular domain of MUC16.

Abstract: Provided herein are anti-CCR8 antibodies or antigen binding fragment thereof, which bind to CCR8, wherein the CCR8 is a human CCR8 and the antibody does not bind human CCR4. The anti-CCR8 antibodies or antigen binding fragment of the disclosure are useful for the treatment of cancer diseases through the elimination of regulatory T cells. Also provided herein are methods of use for the anti-CCR8 antibodies or antigen binding fragment thereof.

Abstract: Provided herein are anti-CCR8 antibodies or antigen binding fragment thereof, which bind to CCR8, wherein the CCR8 is a human CCR8 and the antibody does not bind human CCR4. The anti-CCR8 antibodies or antigen binding fragment of the disclosure are useful for the treatment of cancer diseases through the elimination of regulatory T cells. Also provided herein are methods of use for the anti-CCR8 antibodies or antigen binding fragment thereof.

Abstract: Provided herein are anti-EGFRvII antibodies and binding fragments thereof. The anti-EGFRvIII antibodies of the disclosure are useful for the treatment of cancers through, e.g., antibody-dependent cell cytotoxicity (ADCC). Also provided herein are methods of making and using the anti-EGFRvIII antibodies for the treatment of cancer, and polynucleotides that encode the same.

Abstract: Provided herein are PD-1 agonist antibodies which bind PD-1. The PD-1 agonist antibodies of the disclosure are useful for the treatment of autoimmune and inflammatory diseases through the promotion of PD-1 signaling. Also provided herein are methods of use for the PD-1 agonist antibodies.

Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of several reference protein structures, e.g., related antibody epitopes or protein binding sites. A Machine Learning (ML) model may be used to generate engineered polypeptides. After substituting target residues for corresponding residues in other reference structures in the same scaffold, the scaffolds with each set of target residues may be filtered by structural comparison to identify generalized scaffolds. Generalized scaffolds may be improved by screening libraries of polypeptides.

Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases.

Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of a reference protein structure, e.g., an antibody epitope or a protein binding site. A Machine Learning (ML) model is trained by labeling blueprint records generated from a reference target structure with scores calculated based on computational protein modeling of polypeptide structures generated by the blueprint records. The method may include training an ML model based on a first set of blueprint records, or representations thereof, and a first set of scores, each blueprint record from the first set of blueprint records associated with each score from the first set of scores. After the training, the machine learning model may be executed to generate a second set of blueprint records. A set of engineered polypeptides are then generated based on the second set of blueprint records.

Abstract: Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.

Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of a reference protein structure, e.g., an antibody epitope or a protein binding site. A Machine Learning (ML) model is trained by labeling blueprint records generated from a reference target structure with scores calculated based on computational protein modeling of polypeptide structures generated by the blueprint records. The method may include training an ML model based on a first set of blueprint records, or representations thereof, and a first set of scores, each blueprint record from the first set of blueprint records associated with each score from the first set of scores. After the training, the machine learning model may be executed to generate a second set of blueprint records. A set of engineered polypeptides are then generated based on the second set of blueprint records.

Abstract: Provided herein engineered peptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a reference target, and methods of selecting said engineered peptides. Further provided are methods of using the engineered peptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules.

Abstract: Provided herein are methods for design of engineered polypeptides that recapitulate molecular structure features of a predetermined portion of a reference protein structure, e.g., an antibody epitope or a protein binding site. A Machine Learning (ML) model is trained by labeling blueprint records generated from a reference target structure with scores calculated based on computational protein modeling of polypeptide structures generated by the blueprint records. The method may include training an ML model based on a first set of blueprint records, or representations thereof, and a first set of scores, each blueprint record from the first set of blueprint records associated with each score from the first set of scores. After the training, the machine learning model may be executed to generate a second set of blueprint records. A set of engineered polypeptides are then generated based on the second set of blueprint records.

Abstract: The present invention provides novel porous copolymer films, compositions comprising such films, methods for making such films, and pre-polymerization mixes that can be used for making such films.